Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Degradation

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    74 result(s) found for: Degradation. Displaying page 1 of 4.
    1  2  3  4  Next»
    EudraCT Number: 2007-003913-15 Sponsor Protocol Number: ANTRAG01 Start Date*: Information not available in EudraCT
    Sponsor Name:Medical University Innsbruck
    Full Title: Wirkung von Oxcarbazepin (Trileptal) auf den Kortikosteroid-Metabolismus - Pilotstudie
    Medical condition: Oxcarbazepin, a widely-used antiepileptic treatment is evaluated with respect to Cortisol-degradation. Young adults and adults with oxcarbazepine monotherapy since at least 6 months and temporal lo...
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2021-000434-34 Sponsor Protocol Number: UMCU-VASC-CO-003 Start Date*: 2023-04-12
    Sponsor Name:University Medical Centre Utrecht
    Full Title: A placebo-controlled, double-blind randomized trial evaluating the effect of etidronate in young patients with pseudoxanthoma elasticum on ectopic mineralization.
    Medical condition: Pseudoxanthoma elasticum
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-024449-65 Sponsor Protocol Number: 159:2010/526806 Start Date*: 2011-02-22
    Sponsor Name:Västerbottens läns landsting
    Full Title: Will there be lipid changes during dialysis with Citrasate as dialysate compared to conventional dialysis.
    Medical condition: Chronic haemodialysis patients 18 years upwards. Patients should be in a stable condition during their chronic dialysis program (no ongoing infections or active extensive tumour with CRP above 30 m...
    Disease: Version SOC Term Classification Code Term Level
    10066622 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-005681-37 Sponsor Protocol Number: CL/BIO/15-005 Start Date*: 2016-04-18
    Sponsor Name:BIOIBERICA S.A.
    Full Title: Evaluation of the evolution of imaging markers of cartilage degradation in patients with knee osteoarthritis receiving DROGLICAN®: a Pilot Study
    Medical condition: Knee Osteoarthritis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2022-003825-24 Sponsor Protocol Number: 2059/2022 Start Date*: 2024-03-15
    Sponsor Name:Medical University of Vienna
    Full Title: Drug Concentration and degradation profiles of steroid and antibiotic eye drops in human aqueous humor.
    Medical condition: Postoperative inflammatory response - pharmakokinetics of steroids and antibiotics applied as eye drops
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-005349-29 Sponsor Protocol Number: CSP.XEL1005 Start Date*: 2016-02-15
    Sponsor Name:Xellia d.o.o.
    Full Title: Plasma levels of crystalline degradation product 1 (CDP-1) in vancomycin- treated patients with normal or impaired renal function
    Medical condition: Not applicable: medical conditions or diseases will not be investigated in this trial. In this trial pharmacokinetic parameters of vancomycin and its degradation products will be determined in bl...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: HR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-003671-17 Sponsor Protocol Number: NANOPRO Start Date*: 2021-02-15
    Sponsor Name:Centre François Baclesse
    Full Title: Nanoparticle reirradiation and hypofractionated protontherapy of pan-tumor relapse: non-randomized phase II study.
    Medical condition: recurrent tumors
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038111 Recurrent cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-002368-42 Sponsor Protocol Number: LUM-001 Start Date*: 2017-10-12
    Sponsor Name:Lument AB
    Full Title: An open, randomized, controlled, single centre trial to evaluate CT image quality and diagnostic feasibility of Lumentin® 44, a new egg albumen based oral bowel filling agent, in comparison with di...
    Medical condition: None. Lumentin 44 is a contrast agent and the contrast properties will be investigated in this trial. Patients referred to computerised tomography of the abdomen will be included in the trial. Nei...
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004848 10011603 CT scan LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-004082-39 Sponsor Protocol Number: GOOD-IDES-01 Start Date*: 2017-01-23
    Sponsor Name:Linköping University
    Full Title: An Open-Label Phase II Study in anti-GBM disease (Goodpasture’s disease) with Adverse Renal Prognosis to Evaluate the Efficacy and Safety of IdeS --GOOD-IDES
    Medical condition: Anti-GBM disease (Goodpasture’s disease) with Adverse Renal Prognosis
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004848 10063039 Anti-GBM antibody LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DK (Completed) AT (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2018-003258-25 Sponsor Protocol Number: X16120 Start Date*: 2019-07-04
    Sponsor Name:Odense University Hospital
    Full Title: Bone Study Bone Healing During Ninlaro Exposure. An open label phase 2 single centre clinical trial
    Medical condition: multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-006646-12 Sponsor Protocol Number: POMAlternative Start Date*: 2024-04-25
    Sponsor Name:Amsterdam UMC
    Full Title: Alternative dosing scheme of pomalidomide 4 mg every other day versus pomalidomide 2 mg and 4 mg every day: reduction in costs, same efficacy? A PKPD bioequivalence pilot study.
    Medical condition: Multiple myeloma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-002241-18 Sponsor Protocol Number: 983.974.742 Start Date*: 2023-03-14
    Sponsor Name:Helse Bergen HF
    Full Title: Diagnostic treatment-trial for autonomous cortisol secretion- a tool to select patients for adrenalectomy
    Medical condition: autonomous cortisol secretion
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-020048-36 Sponsor Protocol Number: HGT-HIT-045 Start Date*: 2011-01-31
    Sponsor Name:Shire HGT, Inc
    Full Title: A Phase I/II, Randomized, Safety and Ascending Dose Ranging Study of Intrathecal Idursulfase-IT administered in conjunction with intravenous Elaprase in Pediatric Patients with Hunter Syndrome and ...
    Medical condition: Treatment of Hunter syndrome and cognitive impairment
    Disease: Version SOC Term Classification Code Term Level
    14.1 10010331 - Congenital, familial and genetic disorders 10056889 Mucopolysaccharidosis II PT
    Population Age: Children, Adolescents, Under 18 Gender: Male
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2004-001529-88 Sponsor Protocol Number: LOC 04/2004-01 Start Date*: 2004-11-08
    Sponsor Name:Medical University of Vienna
    Full Title: Dose efficacy relation of inhalative prostaglandin I2 vs. inhalative prostaglandin E1 in patients with ARDS: comparison of efficacy with respect to paO2/FiO2 ratio, Qs/Qt and PAP.
    Medical condition: Patients suffering from ARDS who need in the moment of enrolment artificial respiration
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-001375-11 Sponsor Protocol Number: not applicable Start Date*: 2007-05-16
    Sponsor Name:
    Full Title: Effects and health economic aspects of enzyme therapy in children and adults with Pompe disease Long-term follow-up of patients receiving commercially available Myozyme
    Medical condition: Pompe disease (glycogen storage disease type II) is a genetic, lysosomal storage disorder with a frequency of 1 in 40.000 newborns. The disease is caused by deficiency of alpha-glucosidase, a lysos...
    Disease:
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2008-004699-34 Sponsor Protocol Number: D4260C00008 Start Date*: 2008-10-28
    Sponsor Name:AstraZeneca AB
    Full Title: A Randomised, Double-Blind, Placebo-Controlled, Parallel Group, Phase II study to Assess the efficacy of 28 Day Oral Administration of AZD1236 in Adult Patients with Cystic Fibrosis.
    Medical condition: Cystic Fibrosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10011763 Cystic fibrosis lung LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended) ES (Completed)
    Trial results: View results
    EudraCT Number: 2015-000502-19 Sponsor Protocol Number: PSY-NIL-0002 Start Date*: 2016-06-21
    Sponsor Name:Medical University of Vienna, Department of Psychiatry and Psychotherapy
    Full Title: Effects of sex steroid hormones on serotonin synthesis and degradation measured with PET
    Medical condition: Gender Dysphoria (Female-to-male transsexuals and male-to-female transsexuals)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-001929-40 Sponsor Protocol Number: AZT_DSTB_BB Start Date*: 2017-11-21
    Sponsor Name:University Medical Center Groningen
    Full Title: A prospective, randomized pilot study of the immunomodulatory effects of azithromycin in adults with pulmonary tuberculosis
    Medical condition: Pulmonary tuberculosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10037440 Pulmonary tuberculosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-001314-41 Sponsor Protocol Number: 69501 Start Date*: 2019-05-06
    Sponsor Name:
    Full Title: Kinetics of ivacaftor at Switch Orkambi Symkevi study
    Medical condition: Cystic fibrosis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2005-004455-35 Sponsor Protocol Number: Abscess-Cef-Moxi Start Date*: 2005-11-22
    Sponsor Name:Department of Clinical Pharmacology, Medical University of Vienna
    Full Title: Plasma and abscess fluid pharmacokinetics of cefpirome and moxifloxacin after single dose and multiple dose administration
    Medical condition: Abscess or abdominal cyst
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 28 23:49:06 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA